REGENXBIO (RGNX) Stock Forecast & Price Target

Regenxbio is supported by a broad gene-therapy pipeline and a NAV Technology Platform that continues to advance across retinal, neuromuscular, and neurodegenerative programs, with near-term catalysts still on track despite the RGX-121 clinical hold. The company’s 2Q26 results showed revenue of $108.0M, including a $100M AbbVie milestone, and net income of $22.7M, or $0.43 per share, versus an expected loss, underscoring improving operating leverage and partner validation. Its outlook is further strengthened by the planned RGX-202 rolling BLA starting in 3Q26, completion in 1Q27, and potential accelerated approval in 2H27, while wet AMD and NPDR trials are also advancing toward key 4Q26 and 2027 milestones.

Regenxbio is a clinical-stage gene therapy company whose valuation depends heavily on speculative pipeline assets, with DCF-based asset values of $1.39B to $1.55B offset by only $313M in cash and a $182M liability tied to future royalties. The fundamental outlook is negative because the business still faces low-to-moderate approval probabilities across key programs—55% in wet AMD, 40% in DR, 65% in MPS II, and 55% in DMD—while multiple candidates remain exposed to clinical failure and U.S. regulatory risk. Even if approved, commercial success is uncertain given market size, penetration, and competition, and the prospect of dilution adds further pressure to long-term shareholder value.